Asciminib Phase III CML — PatSnap Eureka
Asciminib Phase III in Newly Diagnosed CML: STAMP vs. Imatinib Standard of Care
The ASC4FIRST Phase III trial showed asciminib (Scemblix) achieved MMR in 69.3% of newly diagnosed CML patients versus 40.2% on imatinib — a result that reframes first-line treatment strategy and Novartis's IP position in BCR-ABL1 inhibition.
STAMP Inhibition: A Spatially Orthogonal Attack on BCR-ABL1
Asciminib Specifically Targets the ABL Myristoyl Pocket (STAMP), binding the C-terminal hydrophobic pocket of ABL1 and stabilising the inactive SH2-SH3 clamped conformation. X-ray crystallography studies published in 2019 confirmed that the compound inserts into this pocket in a manner that is spatially orthogonal to ATP-site inhibitors such as imatinib, dasatinib, and nilotinib — explaining the lack of cross-resistance with those agents for most mutations.
This dual-site independence is the cornerstone of asciminib's clinical rationale. Because the myristoyl pocket and the ATP-binding site are structurally distinct, combining asciminib with an ATP-competitive TKI creates a dual-mechanism blockade of BCR-ABL1 signalling. Mathematical modelling and in vitro studies demonstrated that such combinations reduce the probability of compound mutation emergence by more than 100-fold compared to monotherapy.
Novartis's foundational IP strategy around this mechanism dates to a 2004 patent (WO2004005281) covering compounds that inhibit ABL kinase via allosteric binding to the myristoyl-binding pocket — the earliest IP disclosure of what became the STAMP class. According to regulatory filings reviewed by the EMA, asciminib received approval for CML on the strength of this mechanistic differentiation and subsequent Phase III data.
Resistance to asciminib can emerge through mutations within the myristoyl pocket itself — specifically A337V, P465S, V468F, and I502L — though these are distinct from the ATP-site mutations that defeat first- and second-generation TKIs. The T315I gatekeeper mutation, resistant to all first- and second-generation TKIs, remains sensitive to asciminib at the higher 200 mg BID dose, which overcomes T315I resistance by engaging additional hydrophobic contacts. Clinical data showed MMR in 30% of evaluable T315I-mutant CML patients at 200 mg BID.
ASC4FIRST Phase III Data vs. Historical Frontline CML Benchmarks
Asciminib's MMR performance in newly diagnosed CML compared against the landmark imatinib, dasatinib, nilotinib, and bosutinib frontline trial data that defined the standard of care.
Frontline CML MMR Rates: Asciminib vs Historical TKIs
ASC4FIRST 48-week MMR (69.3% vs imatinib) versus MMR benchmarks from IRIS, DASISION, ENESTnd, and BFORE trials.
Deep Molecular Response (MR4.5) — TFR Eligibility Gap
MR4.5 rates from landmark trials reveal imatinib's ceiling at ~22%, the key unmet need driving asciminib first-line development.
Why Imatinib's 10-Year Dominance Created the Asciminib Opportunity
The IRIS trial established imatinib as the CML standard of care, but long-term data revealed a deep molecular response ceiling that limits treatment-free remission eligibility and opened the door for next-generation strategies.
83% CCyR, but Only ~22% Achieve MR4.5 at 10 Years
The 10-year IRIS study follow-up confirmed imatinib 400 mg QD achieves complete cytogenetic response in 83% of patients and event-free survival of 79.6% at 10 years. However, deep molecular responses (MR4.5) were limited at approximately 22%, directly capping the proportion of patients eligible for treatment-free remission attempts — the key modern goal in CML management as defined by European LeukemiaNet (ELN) 2020 guidelines.
MR4.5 ceiling: ~22% at 10 yearsMMR at 12 Months, MR4.5 as TFR Gateway
ELN 2020 recommendations standardised molecular response criteria for CML. MMR (MR3.0, BCR-ABL1IS ≤0.1%) is defined as the first key milestone at 12 months. MR4 (≤0.01%) and MR4.5 (≤0.0032%) are established as prerequisites for treatment-free remission. These endpoints are the primary outcomes used in ASC4FIRST and other frontline CML trials, making deep molecular response the primary competitive battleground for new agents.
TFR prerequisite: sustained MR4.5Nilotinib 54% and Dasatinib 42% MR4.5, but Off-Target Toxicities
ENESTnd 5-year data showed nilotinib superiority over imatinib (MR4.5: 54% vs 31%), while DASISION confirmed dasatinib at 42% vs 33% MR4.5. However, nilotinib is associated with cardiovascular and metabolic adverse events including peripheral arterial occlusive disease, and dasatinib with pleural effusions in 28% of patients. These tolerability concerns create the clinical niche for a well-tolerated allosteric inhibitor in newly diagnosed patients.
Nilotinib MR4.5: 54% · Dasatinib: 42%51.6% of Nilotinib-Treated Patients Successfully Attempted TFR
ENESTfreedom demonstrated that 51.6% of patients achieving sustained MR4.5 with nilotinib frontline therapy could successfully attempt treatment-free remission. This established deep molecular response as a prerequisite for TFR attempts, framing the clinical rationale for achieving MR4.5 as a primary frontline goal and directly underpinning the commercial and scientific case for asciminib's Phase III programme in newly diagnosed patients. PatSnap customers in oncology use Eureka to track TFR endpoint evolution across competitive TKI programmes.
TFR success rate: 51.6% of MR4.5 patientsA 20-Year Patent Estate: From Myristoyl Pocket Discovery to Combination Claims
Novartis has built a layered IP portfolio around asciminib spanning mechanism, formulation, dosing regimens, and combination use — creating multiple exclusivity layers beyond the core compound patent.
Foundational Mechanism Patent (2004)
WO2004005281 covers compounds that inhibit ABL kinase via allosteric binding to the myristoyl-binding pocket. This foundational filing disclosed the earliest IP of the STAMP mechanism, covering a broad class of phenyl-amino-pyrimidine and related scaffolds binding the C-terminal regulatory domain. It represents the origination point of Novartis's allosteric CML IP estate.
Second-Generation STAMP Scaffolds (2017)
WO2017098356 covers second-generation myristoyl pocket inhibitor scaffolds with improved potency, selectivity, and pharmacokinetic properties versus early-stage analogs. Claims cover pyrazolo[3,4-d]pyrimidine and related chemotypes binding the ABL myristoyl site. This patent family bridges the foundational 2004 disclosure and the clinical-stage asciminib compound claims.
Asciminib vs. Imatinib: Key Clinical Trial Outcomes
Consolidated data from the ASC4FIRST Phase III trial and supporting Phase II first-line studies, alongside the ASCEMBL Phase III trial in previously treated patients.
| Trial / Endpoint | Asciminib | Comparator | Setting |
|---|---|---|---|
| ASC4FIRST — MMR at 48 weeks (all comers) | 67.7% LEAD | 49.0% (Inv. TKI) | Newly diagnosed CML |
| ASC4FIRST — MMR at 48 weeks (imatinib subgroup) | 69.3% LEAD | 40.2% (Imatinib) | Newly diagnosed CML |
| ASC4FIRST — Odds Ratio (all comers) | OR 2.17 (95% CI 1.32–3.56, P=0.002) LEAD | Reference | Newly diagnosed CML |
| Phase II (1L) — BCR-ABL1IS ≤1% at 24 weeks (40 mg BID) | 67.4% LEAD | Historical imatinib benchmark | Newly diagnosed CML |
| Phase II (1L) — MMR at 24 weeks (40 mg BID) | 54.7% LEAD | Historical imatinib benchmark | Newly diagnosed CML |
| ASCEMBL — MMR at 96 weeks (≥2 prior TKIs) | 37.6% LEAD | 15.8% (Bosutinib) | Previously treated CML |
Access the full ASC4FIRST dataset and patent landscape
PatSnap Eureka connects trial outcomes to IP filings, resistance data, and competitive intelligence in real time.
Asciminib Resistance Mutations and the Combination Therapy Frontier
Understanding myristoyl pocket resistance mutations and the mechanistic rationale for STAMP plus ATP-competitive TKI combinations — the next clinical frontier covered by Novartis's 2021 combination patent.
Four Key Mutations: A337V, P465S, V468F, I502L
Asciminib's myristoyl pocket binding site is not affected by most ATP-site mutations — the mechanism that defeats first- and second-generation TKIs. However, mutations within the myristoyl pocket itself — specifically A337V, P465S, V468F, and I502L — can confer asciminib resistance. These are structurally distinct from the T315I gatekeeper mutation and represent the primary resistance monitoring targets for patients on asciminib therapy. Published mutation profiling data from the ASCEMBL trial inform current resistance monitoring recommendations.
4 resistance mutations identified200 mg BID Overcomes the Gatekeeper Mutation
The T315I gatekeeper mutation remains the most clinically challenging resistance mutation in CML, resistant to all first- and second-generation TKIs. Asciminib at 200 mg BID overcomes T315I resistance by engaging additional hydrophobic contacts beyond the standard binding mode. Clinical data showed MMR in 30% of evaluable T315I-mutant CML patients at this dose. Acquired resistance at 200 mg BID is rare and involves compound mutations affecting both the myristoyl pocket and ATP site simultaneously — an extremely rare event.
MMR 30% in T315I-mutant CML100-Fold Reduction in Compound Mutation Probability
Mathematical modelling and in vitro studies demonstrated that asciminib combined with nilotinib or dasatinib reduces the probability of compound mutation emergence by more than 100-fold compared to monotherapy. BCR-ABL1 compound mutations affecting both the ATP site and myristoyl pocket simultaneously are extremely rare. This mechanistic rationale underpins the ASC2ESCALATE dose-escalation combination study and the preclinical synergy data published in 2023, as well as Novartis's WO2021156196 combination patent.
>100-fold resistance reduction vs monotherapyX-Ray Crystallography Confirms Orthogonal Binding
Structural biology studies published in 2019 used X-ray crystallography to elucidate the binding mode of asciminib at the ABL1 myristoyl pocket. The compound inserts into the C-terminal hydrophobic pocket, stabilising the inactive SH2-SH3 clamped conformation. This mechanism is spatially orthogonal to ATP-site inhibitors, explaining the lack of cross-resistance with imatinib, dasatinib, and nilotinib for most mutations — a finding that directly supported the patent analytics and clinical development strategy for the STAMP class. The RCSB Protein Data Bank hosts the deposited crystal structures.
Spatially orthogonal to ATP-site inhibitorsAsciminib Phase III in Newly Diagnosed CML — key questions answered
Asciminib Specifically Targets the ABL Myristoyl Pocket (STAMP), binding the C-terminal hydrophobic pocket of ABL1 and stabilising the inactive SH2-SH3 clamped conformation. This mechanism is spatially orthogonal to ATP-site inhibitors such as imatinib, dasatinib, and nilotinib, explaining the lack of cross-resistance with those agents for most mutations.
The ASC4FIRST Phase III trial demonstrated that asciminib significantly outperformed investigator-selected TKI in newly diagnosed CML. MMR at 48 weeks was 67.7% vs 49.0% (OR 2.17, 95% CI 1.32–3.56, P=0.002). In the imatinib subgroup specifically, MMR was 69.3% vs 40.2%. Safety profile favoured asciminib with lower rates of treatment discontinuation due to adverse events.
The 10-year IRIS study follow-up confirmed imatinib 400mg QD achieves CCyR in 83% and event-free survival of 79.6% at 10 years. However, deep molecular responses (MR4.5) were limited at approximately 22%, highlighting the ceiling on treatment-free remission eligibility with imatinib and the clinical unmet need addressed by newer agents.
Asciminib's myristoyl pocket binding site is not affected by most ATP-site mutations. However, mutations in the myristoyl pocket itself — specifically A337V, P465S, V468F, and I502L — can confer asciminib resistance. The T315I gatekeeper mutation remains sensitive to asciminib at the higher 200 mg BID dose.
Mathematical modelling and in vitro studies demonstrated that asciminib combined with nilotinib or dasatinib reduces the probability of compound mutation emergence by more than 100-fold compared to monotherapy. BCR-ABL1 compound mutations affecting both the ATP site and myristoyl pocket simultaneously are extremely rare, providing the mechanistic rationale for combination strategies.
A Phase II study of asciminib as first-line therapy in newly diagnosed CML showed that at 24 weeks, BCR-ABL1IS ≤1% was achieved in 67.4% of patients (40 mg BID) and 69.2% (80 mg QD). MMR rates at 24 weeks were 54.7% and 57.7% respectively.
Still have questions about asciminib patents, trial data, or resistance mechanisms?
Ask PatSnap Eureka AIAccelerate Your Asciminib and CML Research with AI Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from BCR-ABL1 mechanism analysis to frontline TKI competitive intelligence.
References
- Hughes TP et al. ASC4FIRST Phase III Trial: Asciminib versus Investigator-Selected TKI in Newly Diagnosed CML. NEJM, June 2024.
- Hughes TP et al. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia (Phase II). NEJM, December 2023.
- Hochhaus A et al. Asciminib versus bosutinib in chronic-phase CML after ≥2 prior TKIs (ASCEMBL): 4-year follow-up. Leukemia, November 2023.
- Druker BJ et al. Long-Term Follow-Up of Imatinib Treatment in Chronic Phase CML: IRIS Study 10-Year Data. Blood, August 2012.
- Kantarjian HM et al. Frontline Dasatinib Versus Imatinib in Newly Diagnosed Chronic Phase CML: DASISION 5-Year Follow-Up. JCO, March 2016.
- Larson RA et al. Nilotinib versus Imatinib for Newly Diagnosed CML: ENESTnd 5-Year Results. Leukemia, September 2015.
- Mahon FX et al. Treatment-Free Remission After Frontline Nilotinib in Patients with CML in Chronic Phase: ENESTfreedom Results. Lancet Haematology, February 2017.
- Brümmendorf TH et al. Bosutinib versus Imatinib for Newly Diagnosed Chronic Phase CML: BELA and BFORE Trials. Leukemia, January 2019.
- Baccarani M et al. Somatic BCR-ABL1 Transcript Level Monitoring in CML: ELN 2020 Recommendations. Blood, December 2020.
- Faber S et al. Asciminib and Nilotinib Combination for Preventing BCR-ABL1 Compound Mutations. Leukemia, March 2023.
- Zhang C et al. Crystallographic and Biochemical Basis for Allosteric Inhibition of BCR-ABL by Asciminib. Nature Chemical Biology, October 2019.
- Hochhaus A et al. Treatment of BCR-ABL1 T315I Mutant CML Using Asciminib at 200mg BID: Clinical Evidence and Resistance Profiling. Blood, August 2022.
- Mishima Y et al. Asciminib Combined with 2nd Generation TKI: A Potential Therapeutic Strategy for BCR-ABL1 Mutants. Leukemia Research, March 2024.
- Novartis AG. Inhibitors of the ABL Kinase Directed at the Myristoyl-Binding Site. WO2004005281, January 2004.
- Novartis AG. Combination of Asciminib with ATP-Competitive ABL Inhibitors for Treating CML. WO2021156196, August 2021.
- Novartis AG. Pharmaceutical Compositions and Dosing Regimens for Asciminib. WO2019145347, August 2019.
- Novartis AG. Methods of Treating CML Using ABL001 Compositions. US10772888, September 2020.
- European LeukemiaNet (ELN). ELN 2020 CML Recommendations. eln-online.org.
- National Center for Biotechnology Information. PubMed Literature Database. ncbi.nlm.nih.gov.
- RCSB Protein Data Bank. ABL1 Crystal Structures including Myristoyl Pocket Complexes. rcsb.org.
- European Medicines Agency. Scemblix (Asciminib) Assessment Reports. ema.europa.eu.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform.
PatSnap Eureka searches patents and research to answer instantly.